Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Interest & Investment Income (2016 - 2020)

Corbus Pharmaceuticals Holdings has reported Interest & Investment Income over the past 6 years, most recently at $12649.0 for Q2 2020.

  • For Q2 2020, Interest & Investment Income fell 97.18% year-over-year to $12649.0; the TTM value through Jun 2020 reached $558973.0, down 56.88%, while the annual FY2019 figure was $1.2 million, 24.92% up from the prior year.
  • Interest & Investment Income for Q2 2020 was $12649.0 at Corbus Pharmaceuticals Holdings, down from $101993.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $448717.0 in Q2 2019 and troughed at -$5360.0 in Q1 2016.
  • A 5-year average of $147564.4 and a median of $133073.0 in 2017 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: crashed 1057.14% in 2016 and later surged 14791.73% in 2018.
  • Year by year, Interest & Investment Income stood at $1731.0 in 2016, then surged by 7587.64% to $133073.0 in 2017, then skyrocketed by 83.9% to $244725.0 in 2018, then tumbled by 38.1% to $151477.0 in 2019, then crashed by 91.65% to $12649.0 in 2020.
  • Business Quant data shows Interest & Investment Income for CRBP at $12649.0 in Q2 2020, $101993.0 in Q1 2020, and $151477.0 in Q4 2019.